Cardiac Surgical Procedures, Congenital Heart Disease in Children, Iron Deficiencies, Iron Deficiency Anemia
Conditions
Brief summary
The prevalence of iron deficiency in pediatric cardiac surgery patients is not very well known. Iron deficiency can lead to anemia, higher transfusion rates and possibly higher complication rates. In this retrospective study, the iron status of all patients undergoing pediatric cardiac surgery at our institution between January 2019 and december 2023 will be analyzed. Together with iron status, transfusion requirements as well as complications will be recorded. Iron status will be reported with descriptive statistics, patients with or without iron deficiency will be compared using non-parametric tests.
Interventions
DIAGNOSTIC_TESTIron status
Iron status will be based on preoperative ferritin levels: a ferritin \< 10 mcg/L will be considered as iron deficiency, ferritin levels \> 10 mcg/L will be considered normal
Sponsors
Queen Fabiola Children's University Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 16 Years
Inclusion criteria
* All patients who underwent pediatric cardiac surgery at our institution between January 1, 2019 and December 31, 2023
Exclusion criteria
* Incomplete medical charts * Patients who did not consent to the use of their medical data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of preoperative iron deficiency (%) | 24 hours | A preoperative ferritin \< 10 mcg/L will be considered as iron deficiency. Iron deficiency will be reported using descriptive statistics (mean, standard deviation, median, interquartile range, %) |
| Complications | 28 days | The complication rate (%) will be reported. Complications are defined by the occurence of one or more of the following events: * transfusion rate (%) * volume of packed red cells transfused (mL/kg) * perioperative blood loss (mL/kg) * need for surgical re-exploration (%) * intensive care stay (days) * new renal insufficiency (%) * use of inotropes (%) * 28 day mortality (%) The frequency of any single item will also be reported (%) |
Countries
Belgium
Contacts
Primary ContactDenis Schmartz, MD
Backup ContactAriane Willems, MD, PhD
Outcome results
None listed